Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Laure-Sophie Talagrand"'
Autor:
Anne-Sophie Hamy, Lisa Derosa, Constance Valdelièvre, Satoru Yonekura, Paule Opolon, Maël Priour, Julien Guerin, Jean-Yves Pierga, Bernard Asselain, Diane De Croze, Alice Pinheiro, Marick Lae, Laure-Sophie Talagrand, Enora Laas, Lauren Darrigues, Beatriz Grandal, Elisabetta Marangoni, Elodie Montaudon, Guido Kroemer, Laurence Zitvogel, Fabien Reyal
Publikováno v:
OncoImmunology, Vol 9, Iss 1 (2020)
Immunosurveillance plays an important role in breast cancer (BC) prognosis and progression, and can be geared by immunogenic chemotherapy. In a cohort of 1023 BC patients treated with neoadjuvant chemotherapy (NAC), 40% of the individuals took comedi
Externí odkaz:
https://doaj.org/article/9dd27462f9e14cab8b8dd50e9b410ba2
Autor:
Anne Vincent-Salomon, Fabien Reyal, Beatriz Grandal, Elsy El-Alam, Marick Laé, Anne-Sophie Hamy, Eric Daoud, Lauren Darrigues, Elise Dumas, Guillaume Bataillon, Manon Mangiardi-Veltin, Enora Laas, Laure-Sophie Talagrand, Didier Meseure, Jean-Yves Pierga
Publikováno v:
Cancers
Volume 13
Issue 4
Cancers, Vol 13, Iss 746, p 746 (2021)
Volume 13
Issue 4
Cancers, Vol 13, Iss 746, p 746 (2021)
Simple Summary Immune checkpoint inhibitors (ICI) are now part of the therapeutical arsenal for cancers at several sites and in several settings. PD-L1 expression is assessed to predict treatment response. We used immunohistochemistry (E1L3N clone) t
Autor:
Elsy El-Alam, Beatriz Grandal, Lauren Darrigues, Manon Mangiardi-Veltin, Eric Daoud, Marick Laé, Anne Vincent-Salomon, Guillaume Bataillon, Elise Dumas, Enora Laas, Laure-Sophie Talagrand, Anne-Sophie Hamy, Fabien Reyal, Didier Meseure, Jean-Yves Pierga
The consequences of neoadjuvant chemotherapy (NAC) for PD-L1 activity in triple-negative breast cancers (TNBC) are not well understood. This is an important issue as immune checkpoint inhibitors (ICI) are undergoing rapid development and could be ben
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6d251ae9037404ec047365fedf832985
https://doi.org/10.1101/2020.12.04.20244277
https://doi.org/10.1101/2020.12.04.20244277
Autor:
Bernard Asselain, Guido Kroemer, Enora Laas, Laure-Sophie Talagrand, Lisa Derosa, Elisabetta Marangoni, Maël Priour, Marick Laé, Paule Opolon, Alice Pinheiro, Fabien Reyal, Laurence Zitvogel, Anne-Sophie Hamy, Diane De Croze, Jean-Yves Pierga, Beatriz Grandal, Lauren Darrigues, Julien Guerin, Satoru Yonekura, Constance Valdelièvre, Elodie Montaudon
Publikováno v:
OncoImmunology, Vol 9, Iss 1 (2020)
Oncoimmunology
Oncoimmunology
Immunosurveillance plays an important role in breast cancer (BC) prognosis and progression, and can be geared by immunogenic chemotherapy. In a cohort of 1023 BC patients treated with neoadjuvant chemotherapy (NAC), 40% of the individuals took comedi